A New Way to Grow Tumors in 3-D
If you can grow cancer outside the body, it’s easier to figure out how to kill it. With an eye toward faster drug development and more effective treatments, a UAB biomedical engineer has come up with a new way to sustain cancer cells. It’s a technical challenge, but Joel Berry knows how to explain his system in a digestible way:
“Think of it like making Jello at home.”
But instead of powder and water in a Jello mold for hungry people, it’s collagen in a silicone housing for hungry cancer cells.
“We put it all into a mold, and then we allow that collagen gel to actually form a solid,” says Berry. “And we keep everything profused with a nutrient fluid, and we keep it warm in an incubator, and it’s off to the races.”
Berry calls it a “bioreactor.” The collagen framework inside the housing is intricate, but the whole thing measures only about a cubic centimeter. “Cubic” is key: it’s three-dimensional, unlike, say, a single layer of cells in a petri dish. So the tumors can have volume, as they would in a person.
“We’re going for realism in that we’re creating a three-dimensional tumor, and we’re introducing a flow which is meant to mimic blood flow,” Berry says. “It’s allowed us to do a lot of different things with tumors on the bench-top.”
The engineering feat here is making tiny structures that can withstand fluid being pumped through them and sustain different kinds of cancer cells. Berry calls himself a “plumber,” but he’s a plumber who hopes to play a role in finding faster, cheaper ways to fight cancer.
Sarah Laval, Flickr
These are not humans. So drugs that work on their cancers might not work in humans. But if you could grow someone’s actual cancer cells outside that person and try out all sorts of drugs on it…
Zev Gartner, a pharmaceutical chemist at the University of California, San Francisco, points out that “it can cost anywhere from several hundred million to several billion dollars to develop and get new drugs approved by the pharmaceutical industry.”
He says the high costs and long duration of the process stem partly from drugs that show early promise – say, in mice – but later fail in expensive human trials. Gartner, who’s not affiliated with Berry’s work, says Berry’s bioreactors could cut those costs:
“One fantastic way of doing that would be to reduce the number of drugs that actually go into clinical trials that are likely to fail. And the best way of doing that is to have better models for the interaction of these drugs with humans.”
Along those lines, Gartner sees potential personalized benefits too. Sometimes drugs work for one person but not for someone else with the same kind of cancer. But, “one dream might be to be able to take a biopsy of a tumor and place it in a device and then screen say, 10, 20, maybe even a hundred different combinations of approved drugs and look to see which one works best. We might be able to actually take some of the guesswork out of what drugs to use.”
Berry says his team has made more than a hundred bioreactors and that cancer specialists at UAB are starting to use them in their own labs. If the system continues to work and spread, researchers could theoretically develop better treatments faster, and for less money.
Judge demands to know if White House is helping return wrongly deported Maryland man
The hearing is the first about Abrego Garcia's case since El Salvador's president told reporters he is not going to "smuggle a terrorist into the United States."
Trump signs executive action to lower drug prices
The action is intended to build upon the existing program for Medicare drug price negotiations, which was created by the Inflation Reduction Act that passed during the Biden administration.
Top House Democrat says DOGE data access at NLRB may be ‘technological malfeasance’
A top House Democrat is asking independent agency watchdogs to investigate after NPR reporting revealed DOGE may have taken sensitive data from the National Labor Relations Board.
New Israeli ceasefire offer demands Hamas discuss disarming, but group rejects it
Hamas is rejecting a new Israeli proposal to pause the war in Gaza, a Hamas official told NPR. Earlier, officials mediating talks had expressed optimism that a deal could be reached within weeks.
Higher ed war heats up as Trump threatens Harvard’s tax-exempt status
The president's comments came after the administration froze $2 billion in federal grants for Harvard after the university rejected what it saw as illegal government demands.
U.S. Army libraries target books with a focus on DEI or ‘gender ideology’ for removal
Books "overtly promoting DEI, gender ideology, and critical race theory" are under new scrutiny following a memo issued by acting Assistant Secretary of the Army Derrick Anderson.
